Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 8/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | ACACB | O00763 | 2/20 | 0.51 |
| ▸ | ACACA | Q13085 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619621 | 0.87 | HTR2B (0.60) | CHEK2HPGDHTR2B | |
| SCHEMBL21843704 | 0.84 | HPGD (0.70) | MGLLCHEK2HDAC3HDAC1HDAC8 | |
| SCHEMBL16619560 | 0.83 | MGLL (0.65) | MGLLCHEK2HDAC3HDAC1HDAC8 | |
| SCHEMBL20765842 | 0.81 | HPGD (0.59) | MGLLCHEK2HPGDHTR2B | |
| SCHEMBL20765507 | 0.79 | CHEK2 (0.58) | MGLLCHEK2HPGDBCHEACHE | |
| SCHEMBL16620020 | 0.78 | ALB (0.61) | MGLLCHEK2HDAC3HDAC1HDAC8 | |
| SCHEMBL19970784 | 0.76 | MGLL (0.59) | MGLLCHEK2HDAC3HDAC1HDAC8 | |
| SCHEMBL20765523 | 0.76 | MGLL (0.58) | MGLLCHEK2HDAC3HDAC1HDAC8 | |
| SCHEMBL20765497 | 0.75 | MGLL (0.58) | MGLLCHEK2HDAC3HDAC1HDAC8 | |
| SCHEMBL3178116 | 0.75 | CHEK2 (0.78) | CHEK2HDAC3HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938243-B2 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9809558-B2 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| US-20160221962-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| WO-2015049651-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221962-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | ALB, HDGF, VEGFA | MGLL 3420/4885CHEK2 4260/4885HDAC3 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.